Cooper : COO - 1Q21 IR Presentation FINAL

Investor Presentation

March 4, 2021

Cautionary Statements

Forward-Looking Statements

This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including all statements regarding the expected impact of the ongoing COVID-19 pandemic on our business; and statements regarding acquisitions including the acquired companies' financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities' future expenses, sales and diluted earnings per share are forward-looking. In addition, all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned product launches and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Detailed descriptions of a number of important risk factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements can be found in our Securities and Exchange Commission filings, including under the "Forward-Looking Statements" section in our press releases and under the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in our most recent Annual Report on Form 10-K, as such sections may be updated in our Quarterly Reports on Form 10-Q, copies of which are available on the Company's website:www.coopercos.com. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Non-GAAP Financial Measures

Certain financial measures included in this presentation, or which may be referred to in management's discussion of the Company's results and outlook, are non-GAAP measures that we believe are helpful in understanding our results, for example, constant currency, adjusted EBITDA, non-GAAP earnings per share and non-GAAP margin results. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. Our non-GAAP financial results are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. The reasons that we use these non-GAAP measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are available in our Securities and Exchange Commission filings, including under the "Reconciliation of GAAP Results to Non-GAAP Results" section in our press releases and under the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on the Company's website:www.coopercos.com.

A Leading Medical Device Company

Improving Lives One Person at a Time

CooperCompanies

6.2% Annual Sales Growth from 2015 to 2020

2015

2016

2017

2018

2019

2020

Note: Sales $ in millions

CooperCompanies

Fiscal 2021 Financial Guidance

Sales

FY21 Guidance	Growth vs. FY20
Total	$2,800 - $2,845	12% - 14% cc
CooperVision	$2,090 - $2,120	9% - 11% cc
CooperSurgical	$710 - $725	19% - 22% cc
Non-GAAP	$12.90 - $13.10	34% - 36% asr

EPS

Note: Sales $ in millions; cc means constant currency; asr means as reported;

Non-GAAP and cc - Refer to earnings release for definitions and reconciliation of results

CooperVision

A global leader dedicated to helping improve the way people see each day

Global Soft Contact Lens Market

Market by Competitor

Market by Category

Note: Manufacturers gross sales; Trailing Twelve Months

High Barriers to Entry

• • Highly - specialized manufacturing

• • Technological know-how

• • Stringent FDA and worldwide regulation

• • Long history of product innovation (SiHy with intellectual property)

• • Capital outlay

Favorable Industry Characteristics

• • Limited reimbursement risk

• • Recession resistant

• • Annuity business (stickiness)

• • Underlying wearer growth

• • Strong fundamental growth drivers

Contact Lens Market Drivers

Multiple Growth Drivers

• • Growing global wearer base

• • New fits/trade-up: patients moving to 1 Day

SiHy lenses

New fits

Trade-up

• • Geographic expansion

  Geographic

• • Gerxopwantshioinn Torics and Multifocals

• • Higher net pricing

  Torics Multifocals

• • MyPorpicinag management

Myopia Epidemic

Myopia Expected to Affect Half of the World Population by 2050

4.7 billion

Worldwide Prevalence of Myopia

2000

2010

2020

2030

2040

2050

MiSight® 1 day

First and Only FDA-approved(1) Myopia Management Contact Lens

• • Clinically proven to slow the progression of myopia (nearsightedness) in children by up to 59%(2)

• • Launched Brilliant FuturesTM Myopia Management Program in US in April 2020, and launching in global markets

• • Sold as a program by practitioners and not available online or through distributors

• • Online certification training, marketing and professional support occurring globally

Note: (1) MiSight ® (omafilcon A) daily wear single use Soft Contact Lenses are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of use are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal. (2) When compared tothe children in the control group wearing a single vision 1-day contact lens.

CooperVision

History of Success

Durable Sales Growth

Annual Sales

FY15

FY16

FY17

FY18

FY19

Note: Sales $ in millions

Outpacing Market Growth

FY20

Market Share

CY15

CY16

CY17

CY18

CY19

CY20

CooperVision

Product Category and Geography

Sales by Category

Sales by Geography

Note: FY20

CooperVision

Well Positioned to Succeed

Healthy women, babies and familiesTM

Fertility

Office and Surgical Products

Global Fertility Market

Infertility in couples is high and growing

Global Market(1)

Annual Growth

~15% of couples suffer from infertility

48.5M couples worldwide

Market Growth Drivers

• • Increasing maternal age

• • Greater worldwide disposable income

• • Greater access to treatment

• • Increased patient awareness

Note: (1) Global fertility market includes medical devices, media and genetic testing

Fertility Portfolio Well Positioned for Success

Medical Devices for the IVF Cycle(1)

• • Broadest medical device coverage of the entire IVF cycle(1)

• • Pioneers in IVF genetic testing

• • Market leading IVF tests developed inhouse in state-of-the-art R&D lab

Note: (1) Medical devices for the IVF cycle excludes the consultation and pharma stimulation at the beginning ofthe IVF process

US IUD Market

~2-3% unit growth per year plus priceIncreased awareness and desire for a non-hormonal product

70% of women are concerned about hormones in birth control

Opportunity to shift the US market toward non-hormonal products

Note: "IUD" means Intrauterine Contraceptive Device

• • Only US FDA-approved 100% Hormone Free IUD

• • Over 99% Effective

• • One simple active ingredient - Copper

• • Lasts up to 10 years with Immediate Reversibility

• • In office placement

• • Opportunity to create top of mind awareness

Office & Surgical Medical Devices

Gynecologists

Office-based providers

Obstetrics

Labor & Delivery

Operating room

Opportunity and Drivers

• • Shift to minimally invasive procedures continues

• • Reimbursement is designed to drive procedures to the office

• • Health systems are looking for partnership relationship with vendors

History of Success

FY15

FY16

Note: Sales $ in millions

FY17

FY18

FY19

FY20

Socially and Environmentally Responsible

Committed to enhancing the health and wellness of people and communities locally and globally

Well Positioned for the Future

Operating in two strong markets

Revenue growth exceeding our markets

Investing in the infrastructure of the business and new products

Positioned to achieve long-term objectives

Track record of success